"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"
“HIV-1 抑制患者中卡波西肉瘤的血浆和细胞免疫生物标志物”
基本信息
- 批准号:10871931
- 负责人:
- 金额:$ 10万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcquired Immunodeficiency SyndromeAddressAfricaAfrica South of the SaharaAgeAge YearsAgingAreaAttentionBiological MarkersBiometryCancer PatientCaringCessation of lifeChildChronicChronologyClinicalClinical ResearchCoupledDataData AnalysesData SetDevelopmentDiagnosisDiseaseEducational workshopElderlyElectronicsEthicsFemaleFosteringFutureGenderGenerationsGrantHIVHIV InfectionsHIV SeropositivityHIV-1HIV/AIDSHealthImmunologic MarkersIncidenceInequalityInflammationInfrastructureInstructionInterdisciplinary StudyKaposi SarcomaLife ExpectancyLongevityMalignant NeoplasmsManuscriptsMentorsMothersNatureOceansOutcomeOutputParentsPatient CarePatientsPersonsPlasmaPopulationPreparationPrevalenceProcessProductivityProfessional CompetenceResearchResearch DesignResearch PersonnelResearch PriorityResearch TrainingSample SizeTanzaniaTimeTrainingUnited States National Institutes of Healthage relatedaging populationantiretroviral therapycancer diagnosiscareerco-infectioncohortcomorbiditydata curationdemographicsdesigndisorder controldiversity and inclusionhands on researchimprovedmortalitypandemic diseaserecruitresponsescale upskill acquisitionskillssociodemographicstooltraining opportunitytrend
项目摘要
PROJECT SUMMARY/ABSTRACT
Successful ART coverage has has reduced AIDS-related mortality from 2.2 million in mid 2000s to 1.8
million in 2019. In turn, this has led to global increase in life expectancy of PLWH. In the US, it is estimated
that 50% of the PLWH are older than 50 years and accounts for 70% of total deaths among PLWH. The
ageing population of PLWH is now facing an increase in age-related non-communicable diseases like
cancers. However, in sub-Saharan Africa (SSA) where ~66% of global 38.4 million PLWH reside, data on
the changing demographics of the HIV pandemic are scarce. Although it is expected that non-HIV-
associated malignancies (HIVAM) to increase and at an earlier age at diagnosis as a consequence of
ageing among PLWH, there is limited data on the impact of HIV and ageing on cancer development in
SSA. The limited data on the impact of ageing on health and the nature of the accelerated ageing process
in PLWH in SSA could be partly due to the fact that, 1) prior to ART scale up in Africa, most PLWH were
not treated with ART and died at an earlier age, rarely lived beyond 50 years of age. It is only through ART
a new generation of PLWH are now ageing in SSA. 2) Importantly, in the past, most of the training
opportunities in SSA focused on the training of clinicians to address patient care with minimal emphasis on
research training. Coupled with limited research training opportunities, particularly in HIV and ageing, this
has led to low research output in SSA. To address this gap of well-trained HIV researchers, we are
proposing to recruit and mentor an early-stage female investigator (Dr. Herrieth) on the basics of HIV
research through academic instruction and conducting a hands-on research training to determine the
incidence, trends, and outcome of non-HIVAM in ageing PLWH in Tanzania. The overall objective is to train
the already identified young, enthusiastic female early-stage investigator on expansion of the K43 dataset
to include other cancers in order to determine incidence, trends, and outcomes of non-HIVAM in Tanzania.
We hypothesize that while successful ART improves lifespan of PLWH, but it also lead to an increase in
incidence of non-HIVAM, at an earlier chronological age at cancer diagnosis due to HIV associated chronic
inflammation and unwanted effects of ART. We will utilize the parent K43 study infrastructure to integrate,
and train the early-stage investigator on how to a) design tools for secondary data curation, and b) perform
data analysis to determine incidence, trend, and outcome of non-HIVAM among ageing PLWH. This
training is significant as it provides a unique opportunity for the trainee to acquire skills in HIV and ageing
research. Moreover, the study will foster gender inclusion and diversity in research, motivate others, and
improve the multidisciplinary research workforce. Overall, these efforts will generate preliminary data for
future studies to understand the impact of HIV and ageing to improve health outcomes for PLWH in SSA.
项目总结/文摘
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Clinicopathological Characteristics and Outcomes of Anal Squamous Cell Carcinoma Patients With and Without HIV Infection in Sub-Saharan Africa.
- DOI:10.1200/go.22.00394
- 发表时间:2023-05
- 期刊:
- 影响因子:4.5
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Salum Juma Lidenge其他文献
Salum Juma Lidenge的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Salum Juma Lidenge', 18)}}的其他基金
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"
“HIV-1 抑制患者中卡波西肉瘤的血浆和细胞免疫生物标志物”
- 批准号:
10159996 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"
“HIV-1 抑制患者中卡波西肉瘤的血浆和细胞免疫生物标志物”
- 批准号:
10453941 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"
“HIV-1 抑制患者中卡波西肉瘤的血浆和细胞免疫生物标志物”
- 批准号:
10650452 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"
“HIV-1 抑制患者中卡波西肉瘤的血浆和细胞免疫生物标志物”
- 批准号:
10431995 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"
“HIV-1 抑制患者中卡波西肉瘤的血浆和细胞免疫生物标志物”
- 批准号:
10625456 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 10万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 10万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 10万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 10万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 10万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 10万 - 项目类别:














{{item.name}}会员




